Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer Patients.

Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik BA, Nyirády P, Szendröi A, Szücs M, Módos O, Olah C, Székely E, Reis H, Szarvas T.

Pathol Oncol Res. 2019 Jun 27. doi: 10.1007/s12253-019-00689-y. [Epub ahead of print]

PMID:
31250373
2.

68Ga-PSMA-11 PET Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study.

Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, Briganti A, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP.

J Urol. 2019 Jun 24:101097JU0000000000000417. doi: 10.1097/JU.0000000000000417. [Epub ahead of print]

PMID:
31233369
3.

Molecular Imaging for Primary Staging of Prostate Cancer.

Pomykala KL, Farolfi A, Hadaschik B, Fendler WP, Herrmann K.

Semin Nucl Med. 2019 Jul;49(4):271-279. doi: 10.1053/j.semnuclmed.2019.02.004. Epub 2019 Mar 20. Review.

PMID:
31227050
4.

Factors Associated with Low Sexual Desire in 45-Year-Old Men: Findings from the German Male Sex-Study.

Meissner VH, Schroeter L, Köhn FM, Kron M, Zitzmann M, Arsov C, Imkamp F, Hadaschik B, Gschwend JE, Herkommer K.

J Sex Med. 2019 Jul;16(7):981-991. doi: 10.1016/j.jsxm.2019.04.018. Epub 2019 Jun 10.

PMID:
31196838
5.

Re: Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Hadaschik B, Ost P.

Eur Urol. 2019 May 23. pii: S0302-2838(19)30420-8. doi: 10.1016/j.eururo.2019.05.016. [Epub ahead of print] No abstract available.

PMID:
31130433
6.

[Management of localized prostate cancer].

Hadaschik B, Stief CG.

Urologe A. 2019 May;58(5):485. doi: 10.1007/s00120-019-0932-3. German. No abstract available.

PMID:
31073753
7.

Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.

Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik B, Olah C, Krege S, Nyirády P, Szendröi A, Szücs M, Módos O, Székely E, Reis H, Szarvas T.

Urol Oncol. 2019 Apr 30. pii: S1078-1439(19)30148-6. doi: 10.1016/j.urolonc.2019.04.015. [Epub ahead of print]

PMID:
31053526
8.

[PSA increase after definitive treatment].

Maurer T, Hadaschik B, Budäus L, Steuber T, Salomon G, Horn T, Herrmann K, Weber M, Giesel FL, Berliner C, Eiber M.

Urologe A. 2019 May;58(5):569-582. doi: 10.1007/s00120-019-0931-4. German.

PMID:
31049635
9.

High soluble CGA levels are associated with poor survival in bladder cancer.

Szarvas T, Jardin-Watelet B, Bourgoin N, Hoffmann MJ, Nyirady P, Oláh C, Széll T, Csizmarik A, Hadaschik B, Reis H.

Endocr Connect. 2019 Apr 1. pii: EC-19-0068.R1. doi: 10.1530/EC-19-0068. [Epub ahead of print]

10.

MP20-04 USABILITY AND TECHNICAL FEASIBILITY EVALUATION OF A TETHERED LAPAROSCOPIC GAMMA PROBE FOR RADIOGUIDED SURGERY IN PROSTATE CANCER: A PELVIC PHANTOM AND PORCINE MODEL STUDY.

Adshead J, Oldfield F, Hadaschik B, Wouter Everaerts JA, Mestre-Fusco A, Newbery M, Elson D, Grootendorst MR, Fumado L, Harke NN.

J Urol. 2019 Apr;201(Suppl 4):e284. doi: 10.1097/01.JU.0000555513.09354.e5.

PMID:
30973819
11.

A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.

De Visschere PJL, Standaert C, Fütterer JJ, Villeirs GM, Panebianco V, Walz J, Maurer T, Hadaschik BA, Lecouvet FE, Giannarini G, Fanti S.

Eur Urol Oncol. 2019 Feb;2(1):47-76. doi: 10.1016/j.euo.2018.09.010. Epub 2018 Oct 24. Review.

PMID:
30929846
12.

[Fusion biopsies for primary diagnosis of prostate cancer : Implementation, benefits, and clinical aspects].

Püllen L, Hadaschik B, Eberli D, Kuru TH.

Urologe A. 2019 May;58(5):504-510. doi: 10.1007/s00120-019-0889-2. Review. German.

PMID:
30838429
13.

Re: Minimally Invasive Versus Abdominal Radical Hysterectomy for Cervical Cancer.

Ohlmann CH, Hadaschik B.

Eur Urol. 2019 May;75(5):875. doi: 10.1016/j.eururo.2019.01.029. Epub 2019 Feb 2. No abstract available.

PMID:
30718007
14.

Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.

Tschirdewahn S, Panic A, Püllen L, Harke NN, Hadaschik B, Riesz P, Horváth A, Szalontai J, Nyirády P, Baba HA, Reis H, Szarvas T.

Int J Cancer. 2019 Jul 15;145(2):531-539. doi: 10.1002/ijc.32124. Epub 2019 Jan 31.

PMID:
30650187
15.

Erectile Dysfunction in 45-Year-Old Heterosexual German Men and Associated Lifestyle Risk Factors and Comorbidities: Results From the German Male Sex Study.

Hallanzy J, Kron M, Goethe VE, Köhn FM, Schmautz M, Arsov C, Hadaschik B, Imkamp F, Gschwend JE, Herkommer K.

Sex Med. 2019 Mar;7(1):26-34. doi: 10.1016/j.esxm.2018.11.004. Epub 2019 Jan 9.

16.

[Systemic treatment of metastatic tumors of the upper urinary tract].

Darr C, Hadaschik BA, Tschirdewahn S.

Urologe A. 2019 Jan;58(1):30-33. doi: 10.1007/s00120-018-0835-8. Review. German.

PMID:
30617528
17.
18.

68Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis.

Sachpekidis C, Pan L, Hadaschik BA, Kopka K, Haberkorn U, Dimitrakopoulou-Strauss A.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):351-359. eCollection 2018.

19.

Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer.

Kesch C, Radtke JP, Wintsche A, Wiesenfarth M, Luttje M, Gasch C, Dieffenbacher S, Pecqueux C, Teber D, Hatiboglu G, Nyarangi-Dix J, Simpfendörfer T, Schönberg G, Dimitrakopoulou-Strauss A, Freitag M, Duensing A, Grüllich C, Jäger D, Götz M, Grabe N, Schweiger MR, Pahernik S, Perner S, Herpel E, Roth W, Wieczorek K, Maier-Hein K, Debus J, Haberkorn U, Giesel F, Galle J, Hadaschik B, Schlemmer HP, Hohenfellner M, Bonekamp D, Sültmann H, Duensing S.

Sci Rep. 2018 Nov 12;8(1):16708. doi: 10.1038/s41598-018-35058-3.

20.

Multiparametric MRI and MRI/TRUS Fusion Guided Biopsy for the Diagnosis of Prostate Cancer.

Schütz V, Kesch C, Dieffenbacher S, Bonekamp D, Hadaschik BA, Hohenfellner M, Radtke JP.

Adv Exp Med Biol. 2018;1096:87-98. doi: 10.1007/978-3-319-99286-0_5.

PMID:
30324349
21.

Concordance and Discordance of Sexual Identity, Sexual Experience, and Current Sexual Behavior in 45-Year-Old Men: Results From the German Male Sex-Study.

Goethe VE, Angerer H, Dinkel A, Arsov C, Hadaschik B, Imkamp F, Gschwend JE, Herkommer K.

Sex Med. 2018 Dec;6(4):282-290. doi: 10.1016/j.esxm.2018.08.001. Epub 2018 Sep 28.

22.

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.

Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ.

Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10.

PMID:
30213449
23.

Radiomic Machine Learning for Characterization of Prostate Lesions with MRI: Comparison to ADC Values.

Bonekamp D, Kohl S, Wiesenfarth M, Schelb P, Radtke JP, Götz M, Kickingereder P, Yaqubi K, Hitthaler B, Gählert N, Kuder TA, Deister F, Freitag M, Hohenfellner M, Hadaschik BA, Schlemmer HP, Maier-Hein KH.

Radiology. 2018 Oct;289(1):128-137. doi: 10.1148/radiol.2018173064. Epub 2018 Jul 31.

PMID:
30063191
24.

Nuclear Localization of Robo is Associated with Better Survival in Bladder Cancer.

Krafft U, Reis H, Ingenwerth M, Kovalszky I, Becker M, Niedworok C, Darr C, Nyirády P, Hadaschik B, Szarvas T.

Pathol Oncol Res. 2018 Jul 17. doi: 10.1007/s12253-018-0447-z. [Epub ahead of print]

PMID:
30019121
25.

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.

Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2045-2054. doi: 10.1007/s00259-018-4079-z. Epub 2018 Jul 7.

26.

Sexuality after Male-to-Female Gender Affirmation Surgery.

Hess J, Henkel A, Bohr J, Rehme C, Panic A, Panic L, Rossi Neto R, Hadaschik B, Hess Y.

Biomed Res Int. 2018 May 27;2018:9037979. doi: 10.1155/2018/9037979. eCollection 2018.

27.

The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer.

Darr C, Krafft U, Hadaschik B, Tschirdewahn S, Sevcenco S, Csizmarik A, Nyirady P, Küronya Z, Reis H, Maj-Hes A, Shariat SF, Kramer G, Szarvas T.

Urol Int. 2018;101(1):65-73. doi: 10.1159/000489891. Epub 2018 Jun 27.

PMID:
29949801
28.

Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate.

Bonekamp D, Wolf MB, Roethke MC, Pahernik S, Hadaschik BA, Hatiboglu G, Kuru TH, Popeneciu IV, Chin JL, Billia M, Relle J, Hafron J, Nandalur KR, Staruch RM, Burtnyk M, Hohenfellner M, Schlemmer HP.

Eur Radiol. 2019 Jan;29(1):299-308. doi: 10.1007/s00330-018-5584-y. Epub 2018 Jun 25.

PMID:
29943185
29.

Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.

Lang S, Bruderek K, Kaspar C, Höing B, Kanaan O, Dominas N, Hussain T, Droege F, Eyth C, Hadaschik B, Brandau S.

Clin Cancer Res. 2018 Oct 1;24(19):4834-4844. doi: 10.1158/1078-0432.CCR-17-3726. Epub 2018 Jun 18.

PMID:
29914893
30.

Are there limits of robotic partial nephrectomy? TRIFECTA outcomes of open and robotic partial nephrectomy for completely endophytic renal tumors.

Harke NN, Mandel P, Witt JH, Wagner C, Panic A, Boy A, Roosen A, Ubrig B, Schneller A, Schiefelbein F, Wagener N, Honeck P, Schoen G, Hadaschik B, Michel MS, Kriegmair MC.

J Surg Oncol. 2018 Jul;118(1):206-211. doi: 10.1002/jso.25103. Epub 2018 Jun 7.

PMID:
29878367
31.

Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.

Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Csizmarik A, Ristl R, Puhr M, Hoffmann MJ, Niedworok C, Hadaschik B, Maj-Hes A, Shariat SF, Kramer G.

BJU Int. 2018 Oct;122(4):695-704. doi: 10.1111/bju.14415. Epub 2018 Jun 20.

PMID:
29802777
32.

[New treatment option-apalutamide for nonmetastatic, castration-resistant prostate cancer].

Hadaschik B, Panic A.

Urologe A. 2018 Jun;57(6):729-730. doi: 10.1007/s00120-018-0669-4. German. No abstract available.

PMID:
29789876
33.

Fluorescence-supported lymphography and extended pelvic lymph node dissection in robot-assisted radical prostatectomy: a prospective, randomized trial.

Harke NN, Godes M, Wagner C, Addali M, Fangmeyer B, Urbanova K, Hadaschik B, Witt JH.

World J Urol. 2018 Nov;36(11):1817-1823. doi: 10.1007/s00345-018-2330-7. Epub 2018 May 16.

PMID:
29767326
34.

Genomic features of renal cell carcinoma with venous tumor thrombus.

Warsow G, Hübschmann D, Kleinheinz K, Nientiedt C, Heller M, Van Coile L, Tolstov Y, Trennheuser L, Wieczorek K, Pecqueux C, Gasch C, Kuru T, Nyarangi-Dix J, Hatiboglu G, Teber D, Perner S, Stenzinger A, Roth W, Hadaschik B, Pahernik S, Jäger D, Grüllich C, Duensing A, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Duensing S.

Sci Rep. 2018 May 10;8(1):7477. doi: 10.1038/s41598-018-25544-z.

35.

[Paradigm shift in urology : Prostate cancer diagnosis using MRI-targeted or standard transrectal ultrasonography-guided biopsy].

Hadaschik B.

Urologe A. 2018 Jun;57(6):727-728. doi: 10.1007/s00120-018-0668-5. German. No abstract available.

PMID:
29740666
36.

Discordant prostate specific antigen test results despite WHO assay standardization.

Boegemann M, Arsov C, Hadaschik B, Herkommer K, Imkamp F, Nofer JR, Gerß J, Albers P, Semjonow A.

Int J Biol Markers. 2018 Aug;33(3):275-282. doi: 10.1177/1724600818754750. Epub 2018 May 8.

PMID:
29734838
37.

Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Reis H, Krafft U, Niedworok C, Módos O, Herold T, Behrendt M, Al-Ahmadie H, Hadaschik B, Nyirady P, Szarvas T.

Dis Markers. 2018 Mar 12;2018:7308168. doi: 10.1155/2018/7308168. eCollection 2018. Review.

38.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T.

Int J Cancer. 2018 Apr 19. doi: 10.1002/ijc.31547. [Epub ahead of print]

39.

Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.

Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Kubik A, Romics M, Kovalszky I, Reis H, Hadaschik B, Shariat SF, Kramer G.

Urol Oncol. 2018 Jun;36(6):312.e9-312.e15. doi: 10.1016/j.urolonc.2018.03.010. Epub 2018 Apr 5.

PMID:
29628317
40.

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators.

N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.

41.

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators.

N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.

42.

Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT.

Giesel FL, Will L, Kesch C, Freitag M, Kremer C, Merkle J, Neels OC, Cardinale J, Hadaschik B, Hohenfellner M, Kopka K, Haberkorn U, Kratochwil C.

J Nucl Med. 2018 Apr;59(4):632-635. doi: 10.2967/jnumed.117.196329. Epub 2018 Feb 1.

43.

68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer.

Sachpekidis C, Bäumer P, Kopka K, Hadaschik BA, Hohenfellner M, Kopp-Schneider A, Haberkorn U, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):904-912. doi: 10.1007/s00259-018-3936-0. Epub 2018 Jan 23.

PMID:
29362859
44.

Multiparametric-MRI-Guided Biopsy in the Era of Precision Medicine.

Bergero MA, Martínez PF, Radtke JP, Hadaschik BA.

Arch Esp Urol. 2017 Dec;70(10):833-844. Review. Spanish, English.

PMID:
29205162
45.

PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.

Baranski AC, Schäfer M, Bauder-Wüst U, Roscher M, Schmidt J, Stenau E, Simpfendörfer T, Teber D, Maier-Hein L, Hadaschik B, Haberkorn U, Eder M, Kopka K.

J Nucl Med. 2018 Apr;59(4):639-645. doi: 10.2967/jnumed.117.201293. Epub 2017 Nov 30.

46.

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT.

Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, Hope T, Reiter R, Maurer T, Weber WA, Fendler WP.

J Nucl Med. 2018 Mar;59(3):469-478. doi: 10.2967/jnumed.117.198119. Epub 2017 Nov 9. Erratum in: J Nucl Med. 2018 Jun;59(6):992.

47.

Prospective Multicenter Phase II Study on Focal Therapy (Hemiablation) of the Prostate with High Intensity Focused Ultrasound.

Ganzer R, Hadaschik B, Pahernik S, Koch D, Baumunk D, Kuru T, Heidenreich A, Stolzenburg JU, Schostak M, Blana A.

J Urol. 2018 Apr;199(4):983-989. doi: 10.1016/j.juro.2017.10.033. Epub 2017 Oct 26.

PMID:
29107031
48.

Incidental appendectomy during robotic laparoscopic prostatectomy-safe and worth to perform?

Hüttenbrink C, Hatiboglu G, Simpfendörfer T, Radtke JP, Becker R, Teber D, Hadaschik B, Pahernik S, Hohenfellner M.

Langenbecks Arch Surg. 2018 Mar;403(2):265-269. doi: 10.1007/s00423-017-1630-5. Epub 2017 Nov 2.

PMID:
29098385
49.

Multiparametric MRI fusion-guided biopsy for the diagnosis of prostate cancer.

Kesch C, Schütz V, Dieffenbacher S, Bonekamp D, Hadaschik BA, Hohenfellner M, Radtke JP.

Curr Opin Urol. 2018 Mar;28(2):172-177. doi: 10.1097/MOU.0000000000000461.

PMID:
29083999
50.

Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer.

Hansen NL, Barrett T, Kesch C, Pepdjonovic L, Bonekamp D, O'Sullivan R, Distler F, Warren A, Samel C, Hadaschik B, Grummet J, Kastner C.

BJU Int. 2018 Jul;122(1):40-49. doi: 10.1111/bju.14049. Epub 2017 Nov 15.

Supplemental Content

Loading ...
Support Center